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A B S T R A C T
Pooled data analysis was performed on individual data from 807 pregabalin- and 367 placebo-treated
patients with treatment-resistant partial seizures with or without generalization from four placebo-
controlled studies evaluating the short-term efﬁcacy, safety and tolerability of add-on pregabalin 150–
600 mg/day. Short-term add-on treatment with pregabalin resulted in statistically signiﬁcant reductions
from baseline in seizure frequency and statistically signiﬁcantly higher responder rates over placebo (OR
5.93 [95% CI 4.10, 8.57]). Its overall tolerability was good, with an OR of withdrawing from the study due
to any reason of 1.71 (95% CIs 1.24, 2.35). The most commonly reported AEs were dizziness and
somnolence, however, they were most pronounced during the ﬁrst week of treatment, followed by a
sharp fall in incidences across all dosing groups to<5% fromWeek 2 and onwards. Weight gain, reported
by 5.4–17.1% of patients across pregabalin dosing groups, appeared to be dose-related, but it led to study
withdrawal in only 0.74% (6 out of 810) pregabalin-treated subjects. Our analysis suggests that
pregabalin has a robust efﬁcacy and good tolerability demonstrated in a study population more
treatment-refractory compared to the one enrolled into short-term studies of other new antiepileptic
drugs.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Pregabalin is an alfa-2-delta (a2-d) ligand with anticonvulsant,
analgesic and antianxiety properties. It is thought that pregabalin
binds to the a2d protein subunit, consequently producing
allosteric modulation of p and Q-type voltage gated calcium
channels that results in reduced excitatory neurotransmitter
release.1,2 Pregabalin does not affect GABAergic neurotransmis-
sion: unlike benzodiazepines and barbiturates, it does not
augment GABAergic neurotransmission, nor has any GABA-
reuptake inhibiting effects like tiagabine, or GABA-transaminase
inhibiting effects like vigabatrin. Furthermore, pregabalin treat-
ment, at concentrations that are therapeutically relevant, subtly
but signiﬁcantly reduced the emptying of neurotransmitter
vesicles from presynaptic sites in living neurons in the rat
hippocampus.3* Corresponding author. Tel.: +34 913 875 250; fax: +34 913 875 333.
E-mail addresses: agnagel@ya.com (A. Gil-Nagel),
aetano.zaccara@asf.toscana.it (G. Zaccara), teresa.leon@pﬁzer.com (T. Leon).
1 Tel.: +39 055 275 8894; fax: +39 055 275 8291.
059-1311/$ – see front matter  2008 British Epilepsy Association. Published by Else
oi:10.1016/j.seizure.2008.09.004This apparently occurs by binding of pregabalin toa2d subunits,
and possibly accounting for its actions in vivo to reduce neuronal
excitability and seizures.4 Several studies indicate that the
pharmacology of pregabalin requires binding to a2d subunits,
including structure–activity analyses of compounds binding toa2d
subunits and pharmacology in mice deﬁcient in binding at the a2d
Type 1 protein (for review, see Taylor et al.).4 The preclinical
ﬁndings to date are consistent with a proposed mechanism that
may entail reduction of abnormal neuronal excitability through
reduced neurotransmitter release.4 Pregabalin was found to be
effective against seizures in a wide range of experimental animal
models, as well as in preventing seizures in kindled rats or
genetically susceptible mice.2,4–6 A recent study in mutant mice
containing a single-point mutation within the gene encoding a
speciﬁc auxiliary subunit protein (a2-@-1) of voltage-dependent
calcium channels conclusively demonstrated that analgesic effects
of pregabalin are mediated through this subunit, while establish-
ing it as a therapeutic target for pain control.7
Across the dosing range of 150–600 mg/day, pregabalin has a
linear pharmacokinetic proﬁle with predictable oral absorption
and 90% bioavailability.8 In addition, it does not bind to plasma
proteins, is not hepatically metabolised, is excreted virtuallyvier Ltd. All rights reserved.
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for drug–drug interactions.2,9
The efﬁcacy of pregabalin as an add-on therapy for partial
seizures with or without partial generalisation was evaluated in 4
short-term, randomised, placebo-controlled trials. The aim of the
present analysis was to evaluate the overall efﬁcacy, safety and
tolerability of ﬁxed-dose pregabalin (150–600 mg/day) as add-on
therapy in partial seizures with or without generalisation in a large
patient cohort formed by pooling individual patient data from 4
randomised placebo-controlled trials.
Materials and methods
Included studies
This analysis was based on pooled individual patient data from
3 ﬁxed-dose, 12 week, multicenter, randomised, placebo-con-
trolled trials,10–12 one of which assessed efﬁcacy and safety of b.i.d.
and t.i.d. dosing regimens.12 The fourth study was a placebo-
controlled study with a ﬁxed-dose 600 mg/day arm and ﬂexible-
dose arm.13 Because the ﬂexible-dose arm did not match with any
arms in the other three trials (both in dose and conduct) it could
not be included in the pooled data analyses but results from that
individual study are described herein, and included in the seizure
freedom calculations. The 50 mg/day b.i.d. arm of the French et al.
study10 was also excluded because it was not considered clinically
effective. An overview of study details such as the numbers of
participating centres and countries, dosages, subject numbers in
the intent-to-treat (ITT) population, and dosing periods across
included studies are presented in Table 1.10–13 Results of all four
studies included in this analysis are published in full.
Inclusion and exclusion criteria
Outpatients of either gender aged 18 years11–13 or 12–70
years10 with a history of being refractory to treatment with 2
marketed antiepileptic drugs at maximum tolerated dosages and
inadequate seizure control while on 1–3 standard antiepileptic
drugs were eligible for participation in the studies. The subjects
had to have 6 partial seizures in the 8-week baseline period10–12
or 4 partial seizures in the 6-week baseline period13 prior to
treatment, with no 4-week seizure free interval. Subjects with
evidence or history of haematological, cardiovascular, renal, or
hepatic disease, or signiﬁcant psychiatric disorders were not
eligible for participation in the studies. History of absence of
seizures, treatable causes of seizures, diagnosis of Lennox Gastaut
Syndrome or generalised tonic–clonic status epilepticuswithin theTable 1
Overview of pooled clinical trials
Study Number of patients in th
Placebo Pregabalin
150
Frencha et al.10: 76 centers—USA, Canada 100 86
Arroyo et al.11: 45 centers—Australia, Austria,
Belgium, Finland, France, Germany, Italy,
The Netherlands, UK, South Africa, Spain, Switzerland
96 99
Elger et al.13: 53 centers—Austria, France,
Germany, Italy, Lithuania, Spain, UKb
73 –
Beydoun et al.12: 43 centers—USA, Canada 98 –
Total 367 185
Total pregabalin-treated subjects across three dosing groups 807; total subjects includ
a The subjects participating in the 50 mg/day b.i.d. arm were excluded from the ana
b Only subjects participating in the ﬁxed-dose arm were included in the pooled dataprevious year also precluded participation. Usage of CNS active
drugs was prohibited during the study, except for the current
antiepileptic therapy or stable doses of antidepressant mono-
therapy for mild depression.
Other considerations
Protocols for all studies were approved by local ethical boards
prior to commencement of any study-related activities. The studies
were conducted in compliancewith theDeclaration of Helsinki and
its later revisions, as well as Good Clinical Practice Guidelines.
Randomisation was by computer generated code stratiﬁed by
center using a block size of 6.10–12 The Elger et al.13 study used 1:2
randomisation and a block size of 5. All medication was prepared
as identical looking capsules.
Assessments and outcome variables
The patients were required to maintain a daily seizure diary
during the baseline and double-blind periods, with or without
assistance. The frequency and types of seizures according to the
International Classiﬁcation of Epileptic Seizures14 were deter-
mined by study personnel on the basis of diary entries, and from
these the data percentage change in seizure frequency and
responder rates were calculated. The percentage change was
deﬁned as the percentage change in seizure frequency during
treatment compared with baseline over the last 28-day period,
and was calculated using the following equation: percent
change = [(T  B)/B]  100, where B is the baseline seizure
frequency and T is the seizure frequency during treatment.
However, seizure frequency data can be difﬁcult to analyse
because of high intra- and inter-subject variability, and the
data’s non-parametric nature.15 Non-parametric analyses, such
as the response ratio (RRatio) used as a primary outcome
variable in placebo-controlled pregabalin trials, can be used to
address this problem. The RRatio allows for percentage change
in seizure rate from baseline that is normalised or symmetrised;
its values always fall between 100 and +100, making it
compatible with the parametric statistical data analysis.16
RRatio was calculated using the equation [(T  B)/
(T + B)]  100, where B is the patient’s 28-day baseline seizure
frequency and T is the seizure frequency during treatment.
Negative RRatio values indicate a reduction in the seizure
frequency from baseline. The RRatio range is between 100
(representing seizure freedom), via 0 (indicating no change), to
+100 (indicating an approximately 6-fold increase in seizure
frequency). The direct monotonic transformation of percente ITT group Data acquisition period (weeks)
dose (mg/day) Dosing
schedule
Baseline Titration
period
Fixed-dose
period
300 600
90 89 b.i.d. 8 – 12
– 92 t.i.d. 8 1 11
– 137 b.i.d. 6 – 12
– 214 b.i.d./t.i.d. 8 1 11
90 532
ed in the analysis 1174.
lysis.
analysis.
Table 2
Group characteristics at baseline
Category Overall groupsa Arroyo et al. (2004) French et al. (2003) Beydoun et al. (2005) Elger et al. (2005)
Placebo,
n = 367
All pregabalin,
n = 807
Placebo,
n = 96
All pregabalin,
n = 191
Placebo,
n = 100
All pregabalin,
n = 265
Placebo,
n = 98
All pregabalin,
n = 214
Placebo,
n = 73
All pregabalin,
n = 137
Gender, N (%)
Male 193 (52.6) 393 (48.7) 54 (56.3) 91 (47.6) 52 (52.0) 127 (47.9) 50 (51.0) 106 (49.5) 37 (50.7) 69 (50.4)
Female 174 (47.4) 414 (51.3) 42 (43.8) 100 (52.4) 48 (48.0) 138 (52.1) 48 (49.0) 108 (50.5) 36 (49.3) 68 (49.6)
Race, N (%)
White 331 (90.2) 714 (88.5) 89 (92.7) 177 (92.7) 84 (84.0) 225 (84.9) 87 (88.8) 179 (83.6) 71 (97.3) 133 (97.1)
Black 12 (3.3) 33 (4.1) 1 (1.0) 4 (2.1) 7 (7.0) 19 (7.2) 4 (4.1) 9 (4.2) 0 (0.0) 1 (0.7)
Hispanic 13 (3.5) 41 (5.1) 2 (2.1) 3 (1.6) 7 (7.0) 16 (6.0) 3 (3.1) 20 (9.3) 1 (1.4) 2 (1.5)
Asian or Paciﬁc
islander
2 (0.5) 11 (1.4) 1 (1.0) 3 (1.6) 1 (1.0) 4 (1.5) 0 (0.0) 4 (1.9) 0 (0.0) 0 (0.0)
American Indian
or Alaskan native
0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0)
Other 9 (2.5) 7 (0.9) 3 (3.1) 4 (2.1) 1 (1.0) 1 (0.4) 4 (4.1) 1 (0.5) 1 (1.4) 1 (0.7)
Age (years)
Mean (S.D.) 39.3 (12.3) 38.3 (11.8) 38.1 (12.4) 36.5 (10.9) 39.5 (12.6) 37.7 (11.9) 39.6 (11.8) 38.8 (11.9) 40.3 (12.5) 41.1 (12.2)
Range 16–82 12–75 17–73b 18–70 16–73 12–75 17–82 18–75 18–65 18–71
Seizure aetiology, N (%)
Birth compl. 22 (6.0) 57 (7.1) 13 (13.5) 14 (7.3) 3 (3.0) 18 (6.8) 4 (4.1) 13 (6.1) 2 (2.7) 12 (8.8)
Infections 32 (8.7) 99 (12.3) 8 (8.3) 19 (9.9) 8 (8.0) 35 (13.2) 11 (11.2) 35 (16.4) 5 (6.8) 10 (7.3)
Trauma 49 (13.4) 114 (14.1) 8 (8.3) 19 (9.9) 21 (21.0) 49 (18.5) 16 (16.3) 39 (18.2) 4 (5.5) 7 (5.1)
Family history 23 (6.3) 25 (6.4) 7 (7.3) 14 (7.3) 9 (9.0) 21 (7.9) 5 (5.1) 13 (6.1) 2 (2.7) 4 (2.9)
Structural abn. 16 (4.4) 26 (3.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 16 (21.9) 26 (19.0)
Unknown 177 (48.2) 395 (48.9) 45 (46.9) 101 (52.9) 43 (43.0) 126 (47.5) 54 (55.1) 101 (47.2) 35 (47.9) 67 (48.9)
Other 64 (17.4) 114 (14.1) 21 (21.9) 35 (18.3) 19 (19.0) 35 (13.2) 13 (13.3) 28 (13.1) 11 (15.1) 16 (11.7)
Duration of epilepsy (years)
Mean (S.D.) 23.5 (13.6) 25.7 (12.9) 22.8 (13.6) 25.0 (12.1) 28.7 (14.0) 25.3 (13.3) 23.6 (11.9) 26.8 (13.0) 24.1 (15.6) 25.6 (13.3)
Median 22.1 25.1 21.3 24.1 22.7 25.3 22.6 26.2 24.0 26.0
Range 0.6–63.2 0.6–71.3 2.3–58.3 2.3–53.4 0.8–63.2 1.1–71.3 0.6–53.6 0.6–66.6 1.0–55.0 2.0–60.0
28-day seizure rate at baseline
Mean (S.D.) 32.3 (178.7) 21.2 (34.8) 23.5 (41.1) 22.8 (34.0) 22.3 (42.1) 20.2 (30.2) 25.1 (37.8) 21.4 (40.1) 67.2 (392.7) 20.7 (35.5)
Median 9.5 10.0 9.3 12.0 9.5 9.0 11.0 10.0 8.7 10.0
Range 1.5–3356.7 2.00–435.8 1.5–327.5 2.0–219.0 2.69–311.0 2.00–253.5 2.5–245.0 2.00–435.7 2.67–3365.0 2.00–305.13
Concurrent AEDs, N (%)
1 AED 97 (26.6) 205 (25.5) 23 (24.0) 30 (15.7) 26 (26.0) 79 (29.8) 30 (31.3) 61 (28.8) 18 (24.7) 35 (25.5)
2 AEDs 179 (49.0) 409 (50.8) 42 (43.8) 105 (55.0) 48 (48.0) 139 (52.5) 50 (52.2) 100 (47.2) 39 (53.4) 65 (47.4)
3 AEDs 85 (23.3) 184 (22.9) 30 (31.3) 55 (28.8) 24 (24.0) 47 (17.7) 16 (16.7) 48 (22.6) 15 (20.5) 34 (24.8)
4 AEDs 4 (1.1) 6 (0.7) 1 (1.0) 1 (0.5) 2 (2.0) 0 (0.0) 0 (0.0) 3 (1.4) 1 (1.4) 2 (1.5)
5 AEDs 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7)
a ITT group.
b Two patients were aged 17 years; both patient and their legal representatives gave consent.
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Fig. 1. Percentages reduction in seizure frequency across all treatment groups;
*p < 0.0001 vs. placebo.
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following equation:
RRatio ¼ 100 percentage change
percentage changeþ 200 :
In addition, responder rates according to the regulatory
requirement (i.e. the proportion of patients with 50% reduction
in seizure frequency during treatment compared with baseline)
and seizure freedom for the last 28 days in the study were
calculated as well.17 Incidences (overall and per reason) of
patients prematurely withdrawing from the studies were
calculated for each treatment group. Spontaneously reported or
observed treatment-emergent adverse events (AEs) were
recorded and classiﬁed using the COSTART IV dictionary.18
Laboratory variables and vital signs were also measured during
the studies.
Statistical analysis
All analyses were performed on the ITT group, which comprised
randomised subjects who took at least one dose of blinded study
medication. Group baseline characteristics, drop-out rates and
incidences of AEs were tabulated and compared using descriptive
statistics. The primary efﬁcacy variable, the RRatios, were
compared by using an analysis of variance (ANOVA) model with
treatment and centre as themain effects and the rank of the RRatio
as the dependent variable. The difference in unadjusted means on
unranked raw RRatio data were summarised for each pairwise
group overall, and by centres. A 95% CI for each difference inmeans
was also computed. Generalisabity of the ANOVA model was
examined. Consistency of treatment effects across centers was
explored by adding a treatment-by-centre (interaction term) to the
ANOVA model. To examine generalisability, the interaction term
was tested at a signiﬁcance level of 0.15. Seizure reduction based
on percentage change from baseline was derived by transforma-
tion of the mean RRatio using the equation:
200 RRatio
100 RRatio
Pairwise comparisons were performed by using a step-down
procedure to maintain an overall 5% Type 1 error, and the
pregabalin dose–response relationship was analysed by
testing the linear contrasts from the main ANOVA model. The
responder rates were compared using the Cochran–Mantel–
Haenszel test adjusting for cluster. Odds ratios and correspond-
ing 95% CIs for response with 150, 300, 600 mg/day and all doses
of pregabalin were calculated. Odds ratios and 95% CIs for
withdrawal from pregabalin vs. placebo treatment were also
calculated. Percentages of AEs were tabulated per treatment
group.
Results
Patients’ disposition
There were 1206 randomised subjects (pregabalin, n = 810;
placebo, n = 396), with a total of 1174 subjects comprised
the ITT populations (pregabalin, n = 807; placebo, n = 367) used
for efﬁcacy analyses. The percentage of patients completing
the 12-week treatment period was slightly higher in the
placebo group (308/368, 83.7%) than in the overall pregabalin
group (606/810, n = 74.8%). The most frequent reasons for
premature discontinuation were AEs in both groups (pregabalin,
155/810, 19.1% and placebo, 23/368, 6.3%; OR 3.55, 95% CI 2.25,
5.61).Group characteristics at baseline
Baseline group and disease characteristics were similar across
treatment groups and across studies (Table 2), with approximately
half of the patients beingmale, and their age across studies ranging
between 12 and 82 years. On average, participating patients
experienced epileptic seizures for 26 years (S.D.: 12.7–14.1), with a
median seizure rate between 9 and 12 seizures/28 days, and 74% of
patients were receiving 2 concomitant antiepileptic drugs.
Therewere no relevant differences among the overall treatment
groups regarding seizure etiology, though there were some
differences between studies (Table 2).
Efﬁcacy
Reduction in seizure frequency
Pregabalin-treated patients consistently experienced signiﬁ-
cantly greater reductions in seizure frequency across the 150–
600 mg effective dose range than those on placebo, across the
individual trials as well as in the overall analysis. In the individual
trials, statistically signiﬁcant frequency reductions were regis-
tered with pregabalin across all doses studied vs. placebo
(reduction ranges across studies: pregabalin, 16.5 to 50.9% vs.
placebo, 7 to +1.3%). In the pooled data analysis, signiﬁcant
reductions in seizure frequency were demonstrated for all
pregabalin doses studied vs. placebo (Fig. 1), with a positive
linear dose–response relationship (p < 0.0001; based on themain
ANOVA model).
Derivedby transformationof themainRRatio using the formula
:
200meanRRatio
1meanRRatio
Responder rates
Signiﬁcantly greater proportions of pregabalin- than placebo-
treated patients were classiﬁed as responders (i.e. patients who
had 50% reduction in seizure frequency during treatment
compared with baseline). In the individual trials, responder rates
were between 14–31% with pregabalin 150 mg/day, 40% with
300 mg/day and from 43–51% with 600 mg/day compared to 6–
14% with placebo (p  0.0001; Cochran–Mantel–Haenszel test
adjusted for cluster). Similarly, in the pooled data analysis,
statistically signiﬁcantly more pregabalin- than placebo-treated
patients were classiﬁed as responders (Fig. 2).
Fig. 2. Percentages of responders (patients with 50% reduction in seizure frequency vs. baseline): **p  0.0002 vs. placebo; Cochran–Mantel–Haenszel test adjusted for
cluster.
A. Gil-Nagel et al. / Seizure 18 (2009) 184–192188Moreover, the subjects treated with pregabalin had a statisti-
cally signiﬁcantly greater likelihood of becoming a responder than
the subjects treated with placebo, in each dose group studied as
well as in the overall pregabalin group (Fig. 3).
RRatio
Response rate ratioswere calculated for each pregabalin dose as
well as for all doses together, and comparedwith placebo (Table 3).
All pregabalin doses studied aswell as the overall pregabalin group
produced a reduction in seizure frequency, with all differences vs.
placebo being statistically signiﬁcant.
Seizure freedom
The seizure-free period was calculated for the last 28 days in all
the studies. During the last 28 days of treatment, 16 (12.2%)
patients in the pregabalin ﬂexible-dose group, 66 (12.4%) in the
pregabalin 600 mg group, 11 (12.2%) in the pregabalin 300 mg
group, 12 (6.5%) in the pregabalin 150 mg group and 20 (5.4%) in
the placebo group were completely free of seizures. The ﬂexible
group in the Elger study, pooled 300 mg and pooled 600 mg were
statistically signiﬁcant vs. placebo for seizure freedom during the
last 28 days (Table 4).
Tolerability and safety
The overall tolerability of pregabalin was good, with low
percentages of study discontinuations, and with the majority ofFig. 3.Odds ratios and corresponding 95% CI for responsewith 150, 300, 600 mg/day
and all doses of pregabalin (ITT population): p value for testing the difference
between each dose regimen and placebo is derived from an ANCOVA model with
treatment and cluster of centres as main effects and baseline seizure frequency as
covariate: 150 mg/day, p = 0.0002; 300 mg/day, p < 0.0001; 600 mg/day,
p < 0.0001; all pregabalin doses, p < 0.0001.AEs of mild to moderate severity. During the ﬁrst week of
treatment, a total of 0.0, 5.1, 8.9, 18.2 and 7.4% receiving pregabalin
150 (b.i.d.), 150 (t.i.d.), 300 (b.i.d.), 600 (b.i.d.) and 600 (t.i.d.) mg/
day discontinued treatment vs. 1.5% of patients receiving placebo.
The rates of pregabalin-treated patients who discontinued the
studies during weeks 2–12 were similar to the rates in the placebo
group (0.9, 1.2, 2.1, 2.5 and 2.8% in the pregabalin groups vs. 2.3%
patients on placebo (mean/week).
Themost commonAEs (with5% frequency in either treatment
group) are presented in Table 5. The most frequent AEs were
dizziness and somnolence that were typically mild and tended to
resolve with continued treatment, affecting<5% of subjects across
all dosing groups from Week 2 and onwards (Fig. 4).
Weight gain was reported as an AE (via both spontaneous and
solicited reports) across the dose range studied in 4.9–17.1%
pregabalin- vs. 2.5% placebo-treated patients. Clinically signiﬁcant
weight change (i.e. increase or decrease of 7% from baseline
weight) was registered in 20.6% of pregabalin and 5.2% of placebo-
treated patients (p < 0.0001, Chi-square test). The median end-
point weight gain was 2.0 kg in pregabalin and 0.0 in placebo
treated patients, and it was dose-related in affected patients.
Nevertheless, weight gain led to discontinuation in only 6/807
(0.74%) of pregabalin-treated subjects, 4 of whom were in the
600 mg/day b.i.d. dosing group.
Discussion
Results of this pooled data analysis in a cohort of 1174 patients
with treatment-resistant partial seizures with or without general-
ization conﬁrm the short-term efﬁcacy, safety and tolerability of
add-on pregabalin 150–600 mg/day. Short-term add-on treatment
with pregabalin resulted in statistically signiﬁcant reductions from
baseline in seizure frequency and statistically signiﬁcantly higher
responder rates over placebo. Its overall tolerabilitywas good, with
an OR of withdrawing from the study due to any reason of 1.71
(95% CIs 1.24, 2.35). The most frequent reasons for prematureTable 3
RRatios (ITT population)
Treatment group n Mean (S.D.) RRatio range p valuea
Placebo 367 1.78 (27.01) 100; 88.23 –
150 mg/day 185 15.69 (26.50) 100; 53.07 <0.0001
300 mg/day 90 27.80 (36.46) 100; 72.04 <0.0001
600 mg/day 532 33.12 (41.42) 100; 99.47 <0.0001
All pregabalin doses 807 28.53 (38.59) 100; 99.47 <0.0001
a p value for testing the difference between each dose regimen and placebo is
derived from an ANCOVA model with treatment and cluster of centres as main
effects and baseline seizure frequency as covariate.
Table 4
Seizure freedom last 28 days (ITT population)
Placebo,
N = 367
150 mg/ day,
N = 185
300 mg/day,
N = 90
600 mg/day,
N = 532
Flexible 150–600 mg/
day, N = 131
All pregabalin doses,
N = 938
N (%) 20 (5.4%) 12 (6.5%) 11 (12.2%) 66 (12.4%) 16 (12.2%) 105 (11.2%)
p valuea 0.7003 0.0310b 0.005b 0.0170b 0.0011b
a p value for testing the difference between each dose regimen and placebo.
b Statistically different vs. placebo.
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in the placebo group (155/810, 19.1% and 23/368, 6.0%, respec-
tively). The most commonly reported AEs were dizziness and
somnolence, however, they were most pronounced during the ﬁrst
week of treatment, followed by a sharp fall in incidences across all
dosing groups to <5% from Week 2 and onwards. Although
pregabalin 600 mg/day b.i.d. and t.i.d. dosing regimens have been
demonstrated to have superior efﬁcacy over placebo, some
advantages in pharmacodynamics of the t.i.d. regimen may
suggest it would be better tolerated by some patients. Weight
gain, reported by 5.4–17.1% of patients across pregabalin dosing
groups, appeared to be dose-related, but it led to study withdrawal
in only 0.74% (6 out of 810) pregabalin-treated subjects. Weight
gain seen during pregabalin treatment appears to be particularly
pronouncedwith pregabalin 600 mg/day b.i.d., with 4 (66.6%) of all
weight gain related withdrawals occurring with this dosage
regimen. Currently there are no data regarding possible weight
changes during slow up-titration of pregabalin.
Additional data on weight change associated with placebo and
pregabalin were yielded in a mathematical model which described
the weight change data observed in 36 efﬁcacy/safety studies,
placebo-controlled studies of pregabalin across different indica-
tions (3 healthy volunteer studies and 33 double blind studies), the
relationship between placebo or pregabalin exposure, andTable 5
The most common AEs with 5% frequency in either treatment groupa
AEs (%) Placebo (n = 367) Pregabalin 150 m
day (n = 185)
Dizziness 10.1 17.8
Somnolence 10.4 11.4
Ataxia 4.1 5.9
Weight gain 2.5 4.9
Asthenia 9.3 10.8
Diplopia 3.3 5.4
Amblyopia 3.8 5.4
a AEs are presented by decreasing frequency.
Fig. 4. Resolution of dizziness and somnolencidentiﬁed factors affecting this relationship.19,20 Predicted frac-
tional change (i.e. change in weight expressed as a percentage of
baseline weight) reached steady state in 85 days, and was 0.7% for
placebo; 1.6% for pregabalin 150 mg/day; 2.5% for 300 mg/day and
4.2% for 600 mg/day (Fig. 5).
In addition, efﬁcacy and tolerability results of this ﬁxed-dose
studies pooled data analysis compare favourably with the results
of the ﬂexible-dose arm of the Elger et al. study13 (n = 131, 150–
600 mg/day; 2005). Flexible-dose regimen signiﬁcantly reduced
seizure frequency compared to placebo (35.4% vs. 10.6%,
p = 0.0001). Although the ﬂexible dosing regimen was less
efﬁcacious than the ﬁxed-dose regimen (49.3%, p = 0.0337 vs.
ﬂexible regimen), it was superior in terms of tolerability, with less
study withdrawals due to AEs (12.2% vs. 32.8%) and a lower
incidence of reported AEs.
In their meta-analysis, Otoul et al.21 calculated the odds ratios
for response and withdrawal rates with levetiracetam, and
indirectly compared them with the published results for other
new antiepileptic drugs (lamotrigine, tiagabine, topiramate,
oxcarabazepine and zonisamide)22–30 (Table 6). Felbamate and
vigabatrin were not included due to their limited use resulting
from the associated serious AEs (i.e. aplastic anaemia/hepatic
failure and visual ﬁeld defects, respectively). The odds ratio
calculations were based on data from registration trials of newg/ Pregabalin 300 mg/
day (n = 90)
Pregabalin 600 mg/
day (n = 532)
31.1 39.3
17.8 25.6
10.0 19.9
6.7 17.1
12.2 13.9
6.7 11.8
7.8 11.8
e with continued pregabalin treatment.
Fig. 5. Predicted fractional weight change with placebo or pregabalin.
A. Gil-Nagel et al. / Seizure 18 (2009) 184–192190antiepileptic drugs using the Mantel–Haenszel method (Table 6).
The trials were all add-on, randomised, placebo-controlled trials
available in the public domain, evaluating efﬁcacy, tolerability and
safety of new antiepileptic drugs in treatment-resistant partial
seizure epilepsy with or without generalization, using a design
with 4 weeks of baseline and 8 weeks of treatment period. The
results of the Otoul meta-analysis extend previously reported
results of a meta-analysis of antiepileptic drugs and vagal nerve
stimulation, based on a smaller number of trials.31 When our
results are added to the Otoul et al. data, in this indirect
comparison among all new antiepileptic drugs, pregabalin was
associated with the highest odds ratio for achieving response to
treatment compared to placebo [5.93 (4.10, 8.57)], and was in the
group of new antiepileptic drugs with OR of <2 for withdrawal
compared to placebo.
However, it should be noted that the results of the Otoul et al.
meta-analysis21 were based on registration trials of antiepileptic
drugs available in the public domain. In some of them, dosages
differing from those currently used in clinical practice were used.
For example, the dosages of topiramate and oxcarbazepine used in
registration trials were higher than those currently used in clinical
practice.21 It is, however, unlikely that changes in dosage would
have yielded more favourable ORs for both response and with-
drawal. Another meta-analysis,6 based on all randomised con-
trolled trials of currently available antiepileptic drugs in adult
patients with drug resistant epilepsy, obtained through literature
searches and from pharmaceutical companies, yielded similar
results. In the all-dose analysis, among 10 antiepileptic drugs
analysed pregabalin had the second highest odds ratios for 50%Table 6
Mantel-Haenszel odds ratios for response and withdrawal rates with new antiepileptic
Antiepileptic drug
Response rate
Odds ratio (95% CI) O
Lamotrigine [24] 2.87 (1.92, 4.29)
Levetiracetam [25] 5.35 (3.51, 8.16)
Oxcarbazepine [26] 3.49 (2.49, 4.98)
PREGABALIN [27] 5.93 (4.10, 8.57)           1
Tiagabine [28] 3.82 (2.27, 6.43)
Topiramate [29] 5.22 (3.68, 7.40)
Zonisamide [30] 2.98 (1.81, 4.89)responder rates (3.44, 95% CI 2.51–4.71), while in the effective
doses analysis based on data from 9 antiepileptic drugs, pregabalin
had the highest odd ratios (3.68; 95% CI 2.88–5.04). In the odds
ratio withdrawal analysis based on data from 10 antiepileptic
drugs, pregabalin was in the group of 4 antiepileptic drugs with
ORs <1.5. It should be noted that the efﬁcacy measure used in the
above meta-analyses of antiepileptic drugs were response rates,
with response deﬁned as 50% reduction from baseline seizure
frequency, however, it was not possible to take into account
important clinical variables such as seizure duration and severity.
Although seizure freedom represents the ultimate efﬁcacy out-
comemeasure, low seizure freedom rates obtained in add-on trials
for partial seizures of all new antiepileptic drugs and differences in
methodologies used to yield these data, currently represent a
methodological obstacle for using seizure data in meta analyses
and indirect comparisons between antiepileptic drugs.32
Efﬁcacy and tolerability data from our pooled data analysis are
similar to an analysis performed on a levetiracetam registration
studies data set.33,34 Levetiracetam was the last antiepileptic drug
to become available prior to the introduction of pregabalin in 2005/
2006. However, there are some important differences in the design
of levetiracetam and pregabalin studies that should be taken into
account when interpreting the results of the respective analyses,
such as differences in cohort size, duration of the baseline period,
baseline number of seizures, duration of the up-titration period,
study exclusion criteria and level of refractoriness of the study
population. The levetiracetam analysis was based on a smaller
cohort of patients (levetiracetam, n = 589; placebo, n = 310)33;
comparedwith our analysis (pregabalin, n = 810; placebo, n = 396).
All three levetiracetam ﬁxed-dose, placebo-controlled studies
included in the analysis had a 12-week baseline period.35–37 By
contrast, the baseline period in the included pregabalin studies
was 8 weeks in 3 studies and 6 weeks in one study.13 Although the
median baseline number of seizures calculations were performed
using different approaches [i.e. levetiracetam data were presented
as a median number of seizures per week,34 and pregabalin data as
a median number of seizures over a 28-day period], the numbers
are similar (levetiracetam = 2.3, placebo = 1.9,34 pregabalin = 2.5,
placebo, n = 2.4, recalculated from 28-day data). In the levetir-
acetam studies, the baseline period was followed by a 4-week up-
titration,35–37 while only 2 pregabalin studies were followed by a
1-week up-titration.11,12 It is therefore conceivable that using the
identical, prolonged up-titration period in the pregabalin studies
may have improved tolerability, and resulted in a lower rate of
study withdrawals due to AEs. This is also supported by the AEsdrugs vs. placebo (presented in alphabetical order; adapted from Otoul et al.21
Withdrawal rate
dds ratio (95% CI)
1.16 (0.81, 1.66)
1.26 (0.86, 1.84)
2.27 (1.62, 3.17)
.71 (1.24, 2.35)
2.02 (1.30, 3.12)
2.42 (1.56, 3.74)
1.78 (1.03, 3.08)
A. Gil-Nagel et al. / Seizure 18 (2009) 184–192 191analysis in the pregabalin studies, with high incidences of dizziness
and somnolence observed during the ﬁrst week of treatment (see
above) and subsequently decreasing to an incidence of5% during
the latter course of the studies.
It also appears that the pregabalin and levetiracetam cohorts
differed in treatment-refractoriness of the seizure disorder. While
the subjects who were seizure free for at least a 28-day period
during the baseline period where not eligible for participation in
the pregabalin studies, the same or similar exclusion criterion was
not used in the levetiracetam studies. Consequently, the subjects
who were more treatment refractory could have been recruited
into the pregabalin studies. Furthermore, the pregabalin studies
included in this analysis comprised substantially higher percen-
tages of patients who were using 3 antiepileptic drugs
concomitantly than the levetiracetam studies (pregabalin: 23.7%,
placebo: 24.4%; levetiracetam: 3–5.2%, placebo: 3–5%).35–37 Usage
of more antiepileptic drugs has been identiﬁed as an indicator of
treatment refractoriness,38 and also increases the risk of cognitive
and other central nervous system AEs. As the existing differences
between the registration study designs preclude any extensive
indirect comparisons between tolerability proﬁles of new anti-
epileptic drugs, it is possible that data yielded in large scale, simple
naturalistic trials using different up titration strategies, may shed
more light onto this issue. Finally, in contrast to levetiracetam,
pregabalin is licensed in the EU for the treatment of Generalised
Anxiety Disorder (GAD), and also showed favourable effect on
depressive symptoms associatedwith GAD.39 These characteristics
may make pregabalin particularly suitable for treating subjects
with epilepsy and comorbid anxiety and/or depressive symptoms,
frequently encountered in clinical practice.40,41
Conclusions
In conclusion, the data from analysis of pooled patient data
from four short-term placebo studies of pregabalin (150–600 mg/
day) demonstrate that pregabalin is an effective and well tolerated
add-on treatment for partial seizure with or without secondary
generalization. Our analysis suggests that pregabalin has a robust
efﬁcacy demonstrated in a study population more treatment-
refractory compared to the one enrolled into short-term studies of
other new antiepileptic drugs. Because of its proven efﬁcacy on
anxiety and associated depressive symptoms, pregabalin may be
particularly suitable for treating subjects with epilepsy and
comorbid anxiety/depressive symptoms, frequently encountered
in everyday clinical practice.
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